GHRS

GH Research (GHRS)

About GH Research (GHRS)

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Details

Daily high

$13.33

Daily low

$12.63

Price at open

$12.84

52 Week High

$20.50

52 Week Low

$6.85

Market cap

803.9M

Dividend yield

0.00%

Volume

776,629

Avg. volume

268,124

P/E ratio

-17.72

GH Research News